AVTX

About AVTX

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).